Cargando…
Local Control after Locally Ablative, Image-Guided Radiotherapy of Oligometastases Identified by Gallium-68-PSMA-Positron Emission Tomography in Castration-Sensitive Prostate Cancer Patients (OLI-P)
SIMPLE SUMMARY: In this clinical trial, 63 patients with a total of 89 prostate cancer metastases identified on PSMA-PET were included, none of them undergoing androgen deprivation therapy. We showed that local ablative radiotherapy controls >90% of the metastases, but progression at other sites...
Autores principales: | Hölscher, Tobias, Baumann, Michael, Kotzerke, Jörg, Zöphel, Klaus, Paulsen, Frank, Müller, Arndt-Christian, Zips, Daniel, Thomas, Christian, Wirth, Manfred, Troost, Esther G. C., Krause, Mechthild, Löck, Steffen, Lohaus, Fabian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100669/ https://www.ncbi.nlm.nih.gov/pubmed/35565207 http://dx.doi.org/10.3390/cancers14092073 |
Ejemplares similares
-
Intraindividual comparison of [(68) Ga]-Ga-PSMA-11 and [(18)F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis
por: Hoberück, Sebastian, et al.
Publicado: (2021) -
[(68)Ga]Ga-PSMA-11 PET before and after initial long-term androgen deprivation in patients with newly diagnosed prostate cancer: a retrospective single-center study
por: Hoberück, Sebastian, et al.
Publicado: (2020) -
Correlation between FMISO-PET based hypoxia in the primary tumour and in lymph node metastases in locally advanced HNSCC patients
por: Bandurska-Luque, Anna, et al.
Publicado: (2019) -
Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
por: Meyer, Catherine, et al.
Publicado: (2022) -
Diagnostic Impact of Dual-Time PET/CT with (68)Gallium-PSMA in Prostate Cancer and (68)Gallium-DOTATOC in Neuroendocrine Tumors
por: Librizzi, Damiano, et al.
Publicado: (2023)